Developer docs
API playgroundTry for free, no card

Search company profiles

ImQuest BioSciences

Full company profile

uuid000bnzu

Namestring
ImQuest BioSciences
Legal namestring
ImQuest BioSciences Inc.
Websiteurl
imquestbio.com
Company typeenum
Private
Founded yearint
2004
Descriptiontext

ImQuest BioSciences is a preclinical contract research organization (CRO) founded in 2004 and headquartered in Frederick, Maryland, providing laboratory research services to pharmaceutical companies, biotechnology firms (including virtual and start-up companies), academic investigators, and federal laboratories. The company specializes in infectious disease and oncology preclinical research, with capabilities spanning virology (HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, enteric viruses), microbiology (ESKAPE pathogens, drug-resistant bacteria, antifungal testing, biofilm and murine infection models), in vitro toxicology (primary cell toxicity panels, mitochondrial toxicity), immunology (multiparameter flow cytometry, Luminex multiplexing, ELISpot), oncology (the Onco*SENS* 120 cancer cell line platform), microbicides and STI prevention, and molecular biology services. ImQuest operates BSL-2 and BSL-3 containment facilities and provides high-titer virus and bacterial stock production with international shipping certification for Category A and B infectious substances.

The business operates on a fee-for-service model with custom project-based pricing, accessed via direct sales engagement, technical consultation with scientific directors, and a website-based quote request system. Revenue is generated through laboratory testing, custom assay development, virus and bacterial stock production, resistance selection and characterization, and IND-directed preclinical development support for small molecules, natural products, biologics, therapeutic antibodies, and vaccines. The company has secured over $45 million in cumulative NIH funding on behalf of client programs and has supported successful FDA IND and 510K device submissions. ImQuest maintains active scientific visibility through conference participation (International HBV Meeting, ICAR) and collaborations reflected in peer-reviewed publications across npj Vaccines, ACS Infectious Disease, PLOS Pathogens, Hepatology, and Nature Chemical Biology, among others. The firm is founder-led, with Dr. Robert Buckheit Jr. serving as CEO and CSO since 2004, and Robert 'Bobby' Buckheit III leading Sales & Business Development and Immunology/Flow Cytometry services.

Short descriptiontext

ImQuest BioSciences is a preclinical contract research organization (CRO) founded in 2004 in Frederick, Maryland, providing infectious disease, microbiology, oncology, immunology, and toxicology laboratory services to pharmaceutical, biotechnology, academic, and federal clients using BSL-2/BSL-3 facilities and proprietary assay platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFrederick, United States
HQ citystring
Frederick
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
preclinical contract research, antiviral drug development, infectious disease testing, microbiology services, cancer screening assays
Industry4 codes
PRIMARYHLAGAFAH
Immunotoxicology & Immunogenicity Assessment
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)
NAICS code4 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Medical Laboratories621511
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Services-Medical Laboratories8071
  • Services-Testing Laboratories8734
Product category
Preclinical Contract Research
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Research Services
TypeProfessional Services
Description

ImQuest provides preclinical contract research services on a fee-for-service basis. Clients pay for specific laboratory testing, assay development, virus stock production, and other research services. Services range from initial compound screening through IND-directed preclinical development support. Pricing is quote-based and project-specific.

imquestbio.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details1 tier
1Custom project-based pricing
ModelOtherBilling cadenceMulti-year contract
Notes

Fee-for-service model with project-specific pricing based on assay types, number of samples, complexity, and turnaround time requirements. Contact-based quoting process.

imquestbio.com
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

ImQuest BioSciences is a preclinical and infectious disease contract research organization (CRO) that provides fee-for-service laboratory testing and R&D support to pharmaceutical, biotechnology, academic, and government clients. Its core offerings span virology (HIV, HBV, HCV, HDV, respiratory, coronavirus, herpes, Zika/dengue, enteric viruses), microbiology (antibacterial and antifungal testing with in vitro and in vivo models), in vitro toxicology, immunology, molecular biology, microbicides/STI prevention, and oncology screening. Services support compound evaluation from initial screening through IND-directed preclinical development, including virus and bacterial stock production, custom assay development, and FDA submission support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Successfully submitted multiple Investigational New Drug Applications and 510K Device applications to the FDA
+2 more records
Product overview1 text field

ImQuest BioSciences is a preclinical and infectious disease Contract Research Organization (CRO) providing expert laboratory services to evaluate novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer, and inflammatory diseases. The company operates as a single unified service platform with specialized service lines including Virology Services (HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, enteric viruses), Microbiology Services (antibacterial and antifungal testing with in vitro and in vivo models), In Vitro Toxicology Services (primary cell toxicity panels and mitochondrial toxicity assays), Immunology Services (flow cytometry, Luminex cytokine evaluation, ELISpot), Oncology Services (Onco*SENS* platform with 120 cancer cell lines), Microbicides and STI Prevention Services, Molecular Biology Services (nucleic acid, sequencing, cloning, protein analysis), and R&D Support Services. Additional offerings include Virus and Bacterial Stock Production Services, Virus Panels, Bacterial and Fungal Panels, and specialized preclinical models including Neutropenic Thigh, Sepsis, and Galleria Mellonella larval models. Services support evaluation of small molecules, natural products, biologics, therapeutic antibodies, and vaccines from discovery through IND-directed preclinical development.

Product and service24 records
1Onco*SENS* Cancer Screening Platform
CategoryOncology Preclinical Services
Description

Cell-based anti-cancer screening service using 120 cancer cell lines to evaluate small molecules and biologics, with anti-proliferative and clonogenic assays to differentiate cytotoxic from cytostatic modes of action. Used by pharmaceutical and biotechnology clients developing oncology products.

2Virology Services
CategoryVirology Preclinical Services
Description

Comprehensive antiviral drug testing services for DNA and RNA viruses including HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, and enteric viruses. Supports discovery through IND-directed preclinical development for pharmaceutical and biotechnology clients.

3Microbiology Services
CategoryMicrobiology Preclinical Services
Description

Antibacterial and antifungal testing combining in vitro, ex vivo, and in vivo animal model efficacy, toxicity, and mechanism-of-action evaluations for ESKAPE pathogens, clinical strains, and drug-resistant organisms.

4In Vitro Toxicology Services
CategoryIn Vitro Toxicology Services
Description

Primary cell-based in vitro toxicity assays including Cytotoxicity and Mechanism panels, and Mitochondrial Toxicity and Function assays to evaluate off-target effects of pharmaceutical products on liver, cardiac, and kidney tissues.

5Immunology Services
CategoryImmunology Preclinical Services
Description

Assessment of products modulating immune response, including multiparameter flow cytometry, ELISpot/FluoroSpot analysis, Luminex cytokine evaluation, and primary immune cell assays for T, B, and NK cell functions.

6Microbicides and STI Prevention Services
CategoryMicrobicide and STI Prevention Services
Description

Topical microbicide development and STI prevention research assessing activity, mechanism of action, and toxicity against HIV, HSV, HPV, hepatitis viruses, and other STI-relevant organisms.

7Molecular Biology Services
CategoryMolecular Biology Services
Description

Full-service molecular biology support including nucleic acid services, sequencing, molecular cloning, protein analysis, cell-based molecular assays, CRISPR/siRNA/shRNA gene silencing, and lentiviral vector services.

8R&D Support Services
CategoryR&D Support Services
Description

Outsourced research and development support including customized assay design, tissue culture services, ELISA development, flow cytometry, and biochemical and enzymology laboratory services for drug development.

9Virus Stock Production Services
CategoryVirology Stock Production
Description

Production of high-titer and highly infectious virus stocks for laboratory and clinical strains at scales from milliliters to liters, with concentration, characterization, and Certificate of Analysis.

10Bacterial Stock Production Services
CategoryMicrobiology Stock Production
Description

Propagation, concentration, and characterization of bacteria at scales from milliliters to liters, including preparation of crude, lysed, or frozen bacterial pellets with Certificate of Analysis.

11Virus Panels
CategoryVirology Panels
Description

Comprehensive DNA and RNA virus panels including HIV/retroviruses, hepatitis viruses, mosquito-borne viruses, respiratory viruses, herpesviruses, and enteric viruses for antiviral testing.

12Bacterial and Fungal Panels
CategoryMicrobiology Panels
Description

Microbe panels including ESKAPE pathogens, anaerobic organisms, fungal pathogens, tuberculosis, biofilm-forming pathogens, sexually transmitted disease pathogens, and phenotypic/genetically defined drug-resistant panels.

13HIV and Retrovirus Services
CategoryHIV Antiviral Services
Description

Comprehensive anti-HIV drug development services including antiviral activity quantification, mechanism of action evaluation, drug-resistant virus selection and characterization, and NNRTI TACK killing assays.

14HBV Antiviral Testing Services
CategoryHepatitis B Antiviral Services
Description

Multi-parameter microtiter assay for HBV antiviral testing using cell lines and primary human hepatocytes, with endpoints for extracellular/intracellular HBV DNA, cccDNA, pre-genomic RNA, and viral antigens.

15HCV Antiviral Testing Services
CategoryHepatitis C Antiviral Services
Description

Hepatitis C virus antiviral testing using replicon-based evaluations, genotype 1 replicon models, combination antiviral activity analysis, and resistance selection with whole genome sequencing.

16HDV Antiviral Services
CategoryHepatitis D Antiviral Services
Description

Hepatitis Delta Virus stock production and antiviral screening using Huh-END7 cell lines and primary human hepatocytes, with qPCR and immunofluorescent detection endpoints.

17Coronavirus Testing Services
CategoryCoronavirus Antiviral Services
Description

BSL-2 and BSL-3 coronavirus testing capabilities across multiple strains, with range of action assessments, combination analysis, and resistance characterization.

18Respiratory Virus Services
CategoryRespiratory Virus Services
Description

Screening services for influenza, parainfluenza, RSV, human rhinovirus, measles, metapneumovirus, and adenovirus with various assay endpoints including CPE, plaque, and qPCR.

19Herpesvirus Antiviral Services
CategoryHerpesvirus Antiviral Services
Description

Primary screening and secondary assays for HSV-1, HSV-2, CMV, and VZV using plate-based and plaque reduction assays with crystal violet, immunofluorescent staining, or qPCR endpoints.

20Zika, Dengue and Emerging Virus Services
CategoryMosquito-Borne Virus Services
Description

Antiviral drug testing for mosquito-borne viruses including Zika, dengue, chikungunya, West Nile, and yellow fever virus with in vitro, ex vivo, and in vivo models.

21Biofilm Testing Services
CategoryBiofilm Microbiology Services
Description

In vitro biofilm testing for gram-positive and gram-negative bacterial organisms and fungal organisms to study biofilm establishment, growth, and dispersal.

22Neutropenic Thigh Murine Model
CategoryIn Vivo Microbiology Models
Description

In vivo efficacy model for quantitative evaluation of antibacterial and antifungal agents using different dosing regimens against wild-type and resistant bacterial strains.

23Sepsis Murine Model
CategoryIn Vivo Microbiology Models
Description

Mouse peritonitis-sepsis model of infection for testing antimicrobial agents with bacterial counts or survival endpoints.

24Galleria Mellonella Larval Model
CategoryIn Vivo Microbiology Models
Description

In vivo model for rapid and cost-effective assessment of antimicrobial agents using Galleria mellonella larvae prior to transitioning to murine models.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeStrategic or Co-development Partner
Description

ImQuest participates in the annual International HBV Meeting sponsored by the Hepatitis B Foundation, focusing on molecular biology of HBV and development of novel treatment strategies to achieve functional cure.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

SRI Biosciences conducts preclinical virology, infectious disease, and immunology research for government and commercial clients. Comparable specialty focus and BSL infrastructure, serving a similar mix of NIH-funded and biotech clients.

TypeDirect peer
Description

Non-profit preclinical CRO with parallel infectious disease and oncology drug discovery programs. Operates BSL-2/BSL-3 facilities and offers virology, microbiology, and in vivo efficacy models, overlapping directly with ImQuest's core preclinical service lines.

TypeDirect peer
Description

Supplier of specialty biospecimens and provider of cell-based and molecular assay services to pharma and biotech. Comparable client mix and cell-based assay orientation to ImQuest's preclinical work.

4Viracor Eurofins
TypeDirect peer
Description

Specialty infectious disease and immunology laboratory serving pharmaceutical and clinical trial clients. Comparable virology and immune-monitoring capabilities, though more oriented toward clinical sample testing than preclinical drug development.

TypeBroad incumbent
Description

Large publicly traded preclinical CRO offering virology, microbiology, toxicology, and oncology services at global scale. Represents the enterprise incumbent against which ImQuest competes on specialty infectious disease and oncology niches.

TypeBroad incumbent
Description

Global CRO with comprehensive preclinical and clinical service offerings, including virology and infectious disease capabilities. Sets the enterprise procurement benchmark that smaller specialty CROs like ImQuest are measured against.

TypeDirect peer
Description

Preclinical CRO with infectious disease models, toxicology, and in vivo efficacy capabilities serving pharma and biotech clients. Direct overlap with ImQuest's virology, microbiology, and preclinical development service lines.

TypeDirect peer
Description

Specialty biosafety testing and contract research services for biopharma, with virology and microbiology capabilities. Overlaps with ImQuest's viral clearance, virus stock, and microbial testing services, though typically operating at larger scale and integrated into a broader portfolio.

9IIT Research Institute (IITRI)
TypeDirect peer
Description

Independent non-profit preclinical CRO providing toxicology, pharmacology, and infectious disease research services. Comparable in scale and niche orientation to ImQuest, with overlapping antiviral and antibacterial preclinical offerings.

TypeRegional player
Description

Preclinical CRO based in China offering in vivo pharmacology, toxicology, and infectious disease models to global pharma clients. Comparable preclinical service scope to ImQuest, primarily competing on the basis of regional cost and capacity rather than direct US-market overlap.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

ImQuest BioSciences

Preclinical Contract Researchimquestbio.com

ImQuest BioSciences is a preclinical contract research organization (CRO) founded in 2004 in Frederick, Maryland, providing infectious disease, microbiology, oncology, immunology, and toxicology laboratory services to pharmaceutical, biotechnology, academic, and federal clients using BSL-2/BSL-3 facilities and proprietary assay platforms.

What ImQuest BioSciences does

ImQuest BioSciences is a preclinical contract research organization (CRO) founded in 2004 and headquartered in Frederick, Maryland, providing laboratory research services to pharmaceutical companies, biotechnology firms (including virtual and start-up companies), academic investigators, and federal laboratories. The company specializes in infectious disease and oncology preclinical research, with capabilities spanning virology (HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, enteric viruses), microbiology (ESKAPE pathogens, drug-resistant bacteria, antifungal testing, biofilm and murine infection models), in vitro toxicology (primary cell toxicity panels, mitochondrial toxicity), immunology (multiparameter flow cytometry, Luminex multiplexing, ELISpot), oncology (the Onco*SENS* 120 cancer cell line platform), microbicides and STI prevention, and molecular biology services. ImQuest operates BSL-2 and BSL-3 containment facilities and provides high-titer virus and bacterial stock production with international shipping certification for Category A and B infectious substances.

The business operates on a fee-for-service model with custom project-based pricing, accessed via direct sales engagement, technical consultation with scientific directors, and a website-based quote request system. Revenue is generated through laboratory testing, custom assay development, virus and bacterial stock production, resistance selection and characterization, and IND-directed preclinical development support for small molecules, natural products, biologics, therapeutic antibodies, and vaccines. The company has secured over $45 million in cumulative NIH funding on behalf of client programs and has supported successful FDA IND and 510K device submissions. ImQuest maintains active scientific visibility through conference participation (International HBV Meeting, ICAR) and collaborations reflected in peer-reviewed publications across npj Vaccines, ACS Infectious Disease, PLOS Pathogens, Hepatology, and Nature Chemical Biology, among others. The firm is founder-led, with Dr. Robert Buckheit Jr. serving as CEO and CSO since 2004, and Robert 'Bobby' Buckheit III leading Sales & Business Development and Immunology/Flow Cytometry services.

ImQuest BioSciences firmographics

Firmographics
Name
ImQuest BioSciences
Legal name
ImQuest BioSciences Inc.
Website
https://imquestbio.com
Company type
Private
Founded year
2004
Operating status
Operating
Headcount range
11–50 employees
Short description
ImQuest BioSciences is a preclinical contract research organization (CRO) founded in 2004 in Frederick, Maryland, providing infectious disease, microbiology, oncology, immunology, and toxicology laboratory services to pharmaceutical, biotechnology, academic, and federal clients using BSL-2/BSL-3 facilities and proprietary assay platforms.
Ownership category
akta.pro rank

ImQuest BioSciences industry classification

Industry
Product category
Preclinical Contract Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical Laboratories (621511), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Services-Testing Laboratories (8734)
akta.pro industry
PRIMARYHLAGAFAH
Immunotoxicology & Immunogenicity Assessment
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Preclinical Services (Toxicology/Pharmacology/DMPK)
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAGADAA
Bioanalytical Testing (PK/ADA/NAb)

Keywords

  • Preclinical contract research
  • Antiviral drug development
  • Infectious disease testing
  • Microbiology services
  • Cancer screening assays

Where ImQuest BioSciences is headquartered

Location

Headquarters

HQ city
Frederick
HQ country
United States
HQ region
North America

Offices1 record

Markets served

ImQuest BioSciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. Contract Research Services: ImQuest provides preclinical contract research services on a fee-for-service basis. Clients pay for specific laboratory testing, assay development, virus stock production, and other research services. Services range from initial compound screening through IND-directed preclinical development support. Pricing is quote-based and project-specific.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractCustom project-based pricing

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

ImQuest BioSciences product offering

Product offering

Core offering

ImQuest BioSciences is a preclinical and infectious disease contract research organization (CRO) that provides fee-for-service laboratory testing and R&D support to pharmaceutical, biotechnology, academic, and government clients. Its core offerings span virology (HIV, HBV, HCV, HDV, respiratory, coronavirus, herpes, Zika/dengue, enteric viruses), microbiology (antibacterial and antifungal testing with in vitro and in vivo models), in vitro toxicology, immunology, molecular biology, microbicides/STI prevention, and oncology screening. Services support compound evaluation from initial screening through IND-directed preclinical development, including virus and bacterial stock production, custom assay development, and FDA submission support.

Product overview

ImQuest BioSciences is a preclinical and infectious disease Contract Research Organization (CRO) providing expert laboratory services to evaluate novel pharmaceutical products for the treatment and prevention of viruses, bacteria, cancer, and inflammatory diseases. The company operates as a single unified service platform with specialized service lines including Virology Services (HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, enteric viruses), Microbiology Services (antibacterial and antifungal testing with in vitro and in vivo models), In Vitro Toxicology Services (primary cell toxicity panels and mitochondrial toxicity assays), Immunology Services (flow cytometry, Luminex cytokine evaluation, ELISpot), Oncology Services (Onco*SENS* platform with 120 cancer cell lines), Microbicides and STI Prevention Services, Molecular Biology Services (nucleic acid, sequencing, cloning, protein analysis), and R&D Support Services. Additional offerings include Virus and Bacterial Stock Production Services, Virus Panels, Bacterial and Fungal Panels, and specialized preclinical models including Neutropenic Thigh, Sepsis, and Galleria Mellonella larval models. Services support evaluation of small molecules, natural products, biologics, therapeutic antibodies, and vaccines from discovery through IND-directed preclinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • Onco*SENS* Cancer Screening Platform Cell-based anti-cancer screening service using 120 cancer cell lines to evaluate small molecules and biologics, with anti-proliferative and clonogenic assays to differentiate cytotoxic from cytostatic modes of action. Used by pharmaceutical and biotechnology clients developing oncology products.
  • Virology Services Comprehensive antiviral drug testing services for DNA and RNA viruses including HIV, HBV, HCV, HDV, respiratory viruses, coronaviruses, herpesviruses, Zika/Dengue, and enteric viruses. Supports discovery through IND-directed preclinical development for pharmaceutical and biotechnology clients.
  • Microbiology Services Antibacterial and antifungal testing combining in vitro, ex vivo, and in vivo animal model efficacy, toxicity, and mechanism-of-action evaluations for ESKAPE pathogens, clinical strains, and drug-resistant organisms.
  • In Vitro Toxicology Services Primary cell-based in vitro toxicity assays including Cytotoxicity and Mechanism panels, and Mitochondrial Toxicity and Function assays to evaluate off-target effects of pharmaceutical products on liver, cardiac, and kidney tissues.
  • Immunology Services Assessment of products modulating immune response, including multiparameter flow cytometry, ELISpot/FluoroSpot analysis, Luminex cytokine evaluation, and primary immune cell assays for T, B, and NK cell functions.
  • Microbicides and STI Prevention Services Topical microbicide development and STI prevention research assessing activity, mechanism of action, and toxicity against HIV, HSV, HPV, hepatitis viruses, and other STI-relevant organisms.
  • Molecular Biology Services Full-service molecular biology support including nucleic acid services, sequencing, molecular cloning, protein analysis, cell-based molecular assays, CRISPR/siRNA/shRNA gene silencing, and lentiviral vector services.
  • R&D Support Services Outsourced research and development support including customized assay design, tissue culture services, ELISA development, flow cytometry, and biochemical and enzymology laboratory services for drug development.
  • Virus Stock Production Services Production of high-titer and highly infectious virus stocks for laboratory and clinical strains at scales from milliliters to liters, with concentration, characterization, and Certificate of Analysis.
  • Bacterial Stock Production Services Propagation, concentration, and characterization of bacteria at scales from milliliters to liters, including preparation of crude, lysed, or frozen bacterial pellets with Certificate of Analysis.
  • Virus Panels Comprehensive DNA and RNA virus panels including HIV/retroviruses, hepatitis viruses, mosquito-borne viruses, respiratory viruses, herpesviruses, and enteric viruses for antiviral testing.
  • Bacterial and Fungal Panels Microbe panels including ESKAPE pathogens, anaerobic organisms, fungal pathogens, tuberculosis, biofilm-forming pathogens, sexually transmitted disease pathogens, and phenotypic/genetically defined drug-resistant panels.
  • HIV and Retrovirus Services Comprehensive anti-HIV drug development services including antiviral activity quantification, mechanism of action evaluation, drug-resistant virus selection and characterization, and NNRTI TACK killing assays.
  • HBV Antiviral Testing Services Multi-parameter microtiter assay for HBV antiviral testing using cell lines and primary human hepatocytes, with endpoints for extracellular/intracellular HBV DNA, cccDNA, pre-genomic RNA, and viral antigens.
  • HCV Antiviral Testing Services Hepatitis C virus antiviral testing using replicon-based evaluations, genotype 1 replicon models, combination antiviral activity analysis, and resistance selection with whole genome sequencing.
  • HDV Antiviral Services Hepatitis Delta Virus stock production and antiviral screening using Huh-END7 cell lines and primary human hepatocytes, with qPCR and immunofluorescent detection endpoints.
  • Coronavirus Testing Services BSL-2 and BSL-3 coronavirus testing capabilities across multiple strains, with range of action assessments, combination analysis, and resistance characterization.
  • Respiratory Virus Services Screening services for influenza, parainfluenza, RSV, human rhinovirus, measles, metapneumovirus, and adenovirus with various assay endpoints including CPE, plaque, and qPCR.
  • Herpesvirus Antiviral Services Primary screening and secondary assays for HSV-1, HSV-2, CMV, and VZV using plate-based and plaque reduction assays with crystal violet, immunofluorescent staining, or qPCR endpoints.
  • Zika, Dengue and Emerging Virus Services Antiviral drug testing for mosquito-borne viruses including Zika, dengue, chikungunya, West Nile, and yellow fever virus with in vitro, ex vivo, and in vivo models.
  • Biofilm Testing Services In vitro biofilm testing for gram-positive and gram-negative bacterial organisms and fungal organisms to study biofilm establishment, growth, and dispersal.
  • Neutropenic Thigh Murine Model In vivo efficacy model for quantitative evaluation of antibacterial and antifungal agents using different dosing regimens against wild-type and resistant bacterial strains.
  • Sepsis Murine Model Mouse peritonitis-sepsis model of infection for testing antimicrobial agents with bacterial counts or survival endpoints.
  • Galleria Mellonella Larval Model In vivo model for rapid and cost-effective assessment of antimicrobial agents using Galleria mellonella larvae prior to transitioning to murine models.

Quantifiable outcome

  • Successfully submitted multiple Investigational New Drug Applications and 510K Device applications to the FDA
  • +2 more outcomes

Companies that use ImQuest BioSciences

Customer profile

Named customers5 records

Segments4 records

Ideal customer profiles4 records

ImQuest BioSciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

ImQuest BioSciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Hepatitis B FoundationminorStrategic or Co-development PartnerImQuest participates in the annual International HBV Meeting sponsored by the Hepatitis B Foundation, focusing on molecular biology of HBV and development of novel treatment strategies to achieve functional cure.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

ImQuest BioSciences competitors and assessment

Company assessment

Direct peers

  • SRI International (Biosciences): SRI Biosciences conducts preclinical virology, infectious disease, and immunology research for government and commercial clients. Comparable specialty focus and BSL infrastructure, serving a similar mix of NIH-funded and biotech clients.
  • Southern Research: Non-profit preclinical CRO with parallel infectious disease and oncology drug discovery programs. Operates BSL-2/BSL-3 facilities and offers virology, microbiology, and in vivo efficacy models, overlapping directly with ImQuest's core preclinical service lines.
  • BioIVT: Supplier of specialty biospecimens and provider of cell-based and molecular assay services to pharma and biotech. Comparable client mix and cell-based assay orientation to ImQuest's preclinical work.
  • Viracor Eurofins: Specialty infectious disease and immunology laboratory serving pharmaceutical and clinical trial clients. Comparable virology and immune-monitoring capabilities, though more oriented toward clinical sample testing than preclinical drug development.
  • Inotiv: Preclinical CRO with infectious disease models, toxicology, and in vivo efficacy capabilities serving pharma and biotech clients. Direct overlap with ImQuest's virology, microbiology, and preclinical development service lines.
  • BioReliance (MilliporeSigma): Specialty biosafety testing and contract research services for biopharma, with virology and microbiology capabilities. Overlaps with ImQuest's viral clearance, virus stock, and microbial testing services, though typically operating at larger scale and integrated into a broader portfolio.
  • IIT Research Institute (IITRI): Independent non-profit preclinical CRO providing toxicology, pharmacology, and infectious disease research services. Comparable in scale and niche orientation to ImQuest, with overlapping antiviral and antibacterial preclinical offerings.

Broad incumbents

  • Charles River Laboratories: Large publicly traded preclinical CRO offering virology, microbiology, toxicology, and oncology services at global scale. Represents the enterprise incumbent against which ImQuest competes on specialty infectious disease and oncology niches.
  • Labcorp Drug Development (formerly Covance): Global CRO with comprehensive preclinical and clinical service offerings, including virology and infectious disease capabilities. Sets the enterprise procurement benchmark that smaller specialty CROs like ImQuest are measured against.

Regional players

  • PharmaLegacy Laboratories: Preclinical CRO based in China offering in vivo pharmacology, toxicology, and infectious disease models to global pharma clients. Comparable preclinical service scope to ImQuest, primarily competing on the basis of regional cost and capacity rather than direct US-market overlap.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

ImQuest BioSciences social profiles

Digital presence

ImQuest BioSciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

ImQuest BioSciences leadership team

Management profile

Number of profiles

Profiles2 records

ImQuest BioSciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

ImQuest BioSciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ImQuest BioSciences

What does ImQuest BioSciences do?

ImQuest BioSciences is a preclinical and infectious disease contract research organization (CRO) that provides fee-for-service laboratory testing and R&D support to pharmaceutical, biotechnology, academic, and government clients. Its core offerings span virology (HIV, HBV, HCV, HDV, respiratory, coronavirus, herpes, Zika/dengue, enteric viruses), microbiology (antibacterial and antifungal testing with in vitro and in vivo models), in vitro toxicology, immunology, molecular biology, microbicides/STI prevention, and oncology screening. Services support compound evaluation from initial screening through IND-directed preclinical development, including virus and bacterial stock production, custom assay development, and FDA submission support.

Is ImQuest BioSciences a public or private company?

ImQuest BioSciences is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was ImQuest BioSciences founded?

ImQuest BioSciences was founded in 2004. It employs 11 to 50 people.

Where is ImQuest BioSciences based?

ImQuest BioSciences is headquartered in Frederick, United States, in the North America region.

How does ImQuest BioSciences make money?

One revenue line is on record: contract Research Services.

Who are ImQuest BioSciences's main competitors?

Direct peers on record are SRI International (Biosciences), Southern Research, BioIVT, Viracor Eurofins, Inotiv, BioReliance (MilliporeSigma) and IIT Research Institute (IITRI). Broad incumbents are Charles River Laboratories and Labcorp Drug Development (formerly Covance). PharmaLegacy Laboratories is listed as a regional player.

Does ImQuest BioSciences have an API?

No public API is recorded for ImQuest BioSciences.

What industry is ImQuest BioSciences in?

ImQuest BioSciences's product category is Preclinical Contract Research. Its primary akta.pro industry code is HLAGAFAH, Immunotoxicology & Immunogenicity Assessment, with a secondary code of HLAGADAH, Cell-Based & Potency Assays (Bioassays). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireMoleculin Provides Update on Coronavirus Drug DevelopmentMoleculin Biotech announced that the US FDA has granted its request for a Pre-IND Meeting to discuss studying drug candidate WP1122 in a clinical trial for COVID-19, with written responses expected by June 30, 2020. The company has engaged ImQuest BioSciences and IITRI for preclinical support, and initial in vitro testing on HCoV-229E (a surrogate coronavirus) showed WP1122 displayed a greater therapeutic index than 2-DG with 5 to 10-fold inhibition of coronavirus production. Moleculin estimates it can submit its IND application in the second half of 2020, pending FDA guidance.GlobeNewswireWPD Pharmaceuticals and CNS Pharmaceuticals Announce Additional Coronavirus Testing on WP1122 by ImQuest BiosciencesWPD Pharmaceuticals and CNS Pharmaceuticals announced that ImQuest Biosciences will expand in vitro and in vivo testing of WP1122, a drug candidate for COVID-19 treatment. The agreement was entered by Moleculin Biotech, WPD's license partner, and the company stated no claims that the partnership will eliminate or cure the virus.PR NewswireMoleculin Announces Agreement with ImQuest Biosciences to Expand Coronavirus TestingMoleculin Biotech announced it has entered into an agreement with ImQuest Biosciences to expand in vitro and in vivo testing of WP1122, its lead drug candidate for COVID-19 treatment. The agreement follows research by Goethe University Frankfurt showing that 2-DG, the active compound in WP1122, inhibited SARS-CoV-2 replication in susceptible cell lines. The company aims to generate critical data within 4 to 8 weeks to support an Investigational New Drug submission in the US and a Clinical Trial Authorization request in Europe.